Home/ Stocks/ AVTX

Avalo Therapeutics, Inc. Common Stock

AVTX XNAS

$13.45 -0.05 (-0.37%) ▼ 15-min delayed

Open

$13.50

High

$14.78

Low

$13.15

Volume

1.02M

Market Cap

$249.92M

About Avalo Therapeutics, Inc. Common Stock

Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Sector: PHARMACEUTICAL PREPARATIONS Employees: 23 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$0	$-30,625,000	$-2.19
Q2 2025	$0	$-20,765,000	$-1.92
Q1 2025	$0	$-13,149,000	$-1.25
FY 2024	$441.0K	$-35,129,000	$-7.94

Related Market News

No specific coverage for AVTX yet. Check out our latest market news or earnings calendar.

Get AVTX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Avalo Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.